Risks of glaucoma among individuals with psoriasis: a population-based cohort study.

IF 3.7 4区医学 Q1 DERMATOLOGY

Clinical and Experimental Dermatology Pub Date : 2024-08-22 DOI:10.1093/ced/llae073

Shu-Hao Li, Chun-Yu Cheng

{"title":"Risks of glaucoma among individuals with psoriasis: a population-based cohort study.","authors":"Shu-Hao Li, Chun-Yu Cheng","doi":"10.1093/ced/llae073","DOIUrl":null,"url":null,"abstract":"Background: Psoriasis is a chronic systemic disorder with ocular involvement.Objectives: To evaluate the risk of glaucoma among patients with psoriasis.Methods: Participants in this cohort study were selected based on Chang Gung Research Database from 1 January 2003 to 31 December 2012. Follow-up ended on 31 December 2017. The participants in the control group were matched with the psoriasis group by sex, age and index date with a 4 : 1 ratio. The hazard ratios of glaucoma were estimated using Cox regression analysis. We also evaluated the relationship between the risk of glaucoma and systemic therapies as well as phototherapy and topical corticosteroid in patients with psoriasis.Results: In total, 6682 patients with psoriasis and 26 728 matched controls were enrolled. The study population was composed mainly of males accounting for 64.2% (21 445/33 410) of the study population. The psoriasis group had higher incidence rates than the control group for glaucoma (adjusted hazard ratio 1.405, 95% confidence interval, 1.051-1.879). Patients with psoriasis receiving psoralen-ultraviolet A (PUVA) therapy for > 200 sessions had an increased risk of glaucoma.Conclusions: Patients with psoriasis had an increased risk of glaucoma. Long-term PUVA therapy raised the risk of glaucoma in people with psoriasis.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llae073","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Psoriasis is a chronic systemic disorder with ocular involvement.

Objectives: To evaluate the risk of glaucoma among patients with psoriasis.

Methods: Participants in this cohort study were selected based on Chang Gung Research Database from 1 January 2003 to 31 December 2012. Follow-up ended on 31 December 2017. The participants in the control group were matched with the psoriasis group by sex, age and index date with a 4 : 1 ratio. The hazard ratios of glaucoma were estimated using Cox regression analysis. We also evaluated the relationship between the risk of glaucoma and systemic therapies as well as phototherapy and topical corticosteroid in patients with psoriasis.

Results: In total, 6682 patients with psoriasis and 26 728 matched controls were enrolled. The study population was composed mainly of males accounting for 64.2% (21 445/33 410) of the study population. The psoriasis group had higher incidence rates than the control group for glaucoma (adjusted hazard ratio 1.405, 95% confidence interval, 1.051-1.879). Patients with psoriasis receiving psoralen-ultraviolet A (PUVA) therapy for > 200 sessions had an increased risk of glaucoma.

Conclusions: Patients with psoriasis had an increased risk of glaucoma. Long-term PUVA therapy raised the risk of glaucoma in people with psoriasis.

查看原文本刊更多论文

银屑病患者患青光眼的风险：基于人群的队列研究

背景：银屑病是一种慢性全身性疾病，可累及眼部：银屑病是一种累及眼部的慢性全身性疾病：本研究旨在评估银屑病患者罹患青光眼的风险：本队列研究的受试者是根据长庚研究数据库从 2003 年 1 月 1 日至 2012 年 12 月 31 日选出的。随访于2017年12月31日结束。对照组的参与者与银屑病组的参与者按性别、年龄和发病日期以4:1的比例配对。我们使用 Cox 回归分析估算了青光眼的危险比。我们还评估了银屑病患者患青光眼的风险与系统疗法、光疗和局部皮质类固醇激素之间的关系：共有 6,682 名银屑病患者和 26,728 名匹配对照者参加了研究。研究人群主要由男性组成，占研究人群的 64.2%。银屑病组的青光眼发病率高于对照组（调整后的危险比为 1.405 [95% 置信区间为 1.051-1.879]）。接受补骨脂素和紫外线-A（PUVA）治疗超过 200 次的银屑病患者患青光眼的风险更高：结论：银屑病患者患青光眼的风险增加。结论：银屑病患者患青光眼的风险增加，长期接受 PUVA 治疗会增加银屑病患者患青光眼的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

2.40%

发文量

389

审稿时长

3-8 weeks

期刊介绍： Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.